Roche dumps its late-stage SMA drug after gambling up to $545M-plus on the program
After running into repeated setbacks with its experimental drug for spinal muscular atrophy, Roche has opted to scrap the therapy it grabbed three years ago …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
